Drug Trial Radar · NCT06128967
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
399
Actual
Start
Oct 18, 2023
Primary completion
Jul 1, 2025
Study completion Aug 1, 2025
Sponsor
- Lead sponsor
- CardresearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IRB approval date 14-APR-2024 and public at https://plataformabrasil.saude.gov.br/login.jsf since IURB approval Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that follow a known episode of COVID-19 and cannot be explained by another medical condition. This condition is observed in up to 15% of all individuals after an acute episode of COVID-19, even in those who had a mild and oligosymptomatic SARS-CoV-2 infection. Around 40% of these patients present symptoms that significantly compromise their daily activities. There is increasing evidence that LONG COVID is accompanied by dysregulated, persistent and uncontrolled inflammation, often accompanied by the development of an autoreactive immune response, including autoantibodies. Symptoms can last months or years, particularly in cases of chronic fatigue syndrome, with significant proportions of individuals having significant chronic impairment, preventing the performance of work and social activities.
Conditions
- Long COVID-19 Syndrome
- Chronic Fatigue Syndrome
Interventions
Fluvoxamine Maleate 100 MGDrug
Fluvoxamine Maleate 100 mg each pills
PlaceboDrug
Placebo talc pills of same shape, color, weight if compared with active comparator
Metformin Extended Release Oral TabletDrug
Metformin Extended release oral tablets of 750 mg each pill
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement on Fatigue Severity Score Scale (FSS)Time frame: Day 60 after randomization
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
CARDRESEARCH - Cardiologia Assistencial e de Pesquisa
Belo Horizonte, Minas Gerais, Brazil
City of Brumadinho
Brumadinho, Minas Gerais, Brazil
Governador Valadares City Public Health Authority
Governador Valadares, Minas Gerais, Brazil
City of Ibirité Public Health Authority
Ibirité, Minas Gerais, Brazil
Sociedade Padrao de Educacao Superior
Montes Claros, Minas Gerais, Brazil
Universidade Federal de Ouro Preto
Ouro Preto, Minas Gerais, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.